Abeona Therapeutics Inc [ABEO] stock is trading at $6.23, up 2.13%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABEO shares have gain 11.25% over the last week, with a monthly amount glided 28.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abeona Therapeutics Inc [NASDAQ: ABEO] stock has seen the most recent analyst activity on March 05, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $16. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 03, 2024, and set its price target to $15. On May 30, 2024, Stifel initiated with a Buy rating and assigned a price target of $21 on the stock. Cantor Fitzgerald upgraded its rating to a Overweight but stick to its price target of $4 on November 11, 2020. B. Riley FBR initiated its recommendation with a Buy and recommended $5 as its price target on September 18, 2020. SVB Leerink started tracking with a Outperform rating for this stock on February 10, 2020, and assigned it a price target of $6.
Abeona Therapeutics Inc [ABEO] stock has fluctuated between $3.93 and $7.32 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Abeona Therapeutics Inc [NASDAQ: ABEO] shares were valued at $6.23 at the most recent close of the market. An investor can expect a potential return of 188.92% based on the average ABEO price forecast.
Analyzing the ABEO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.86 and Total Capital is -0.86. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Abeona Therapeutics Inc’s Current Ratio is 4.90. On the other hand, the Quick Ratio is 4.90, and the Cash Ratio is 0.89.
Transactions by insiders
Recent insider trading involved Alvino Mark, Director, that happened on May 16 ’25 when 8000.0 shares were sold. Director, Alvino Mark completed a deal on May 16 ’25 to buy 8000.0 shares. Meanwhile, Chief Executive Officer Seshadri Vishwas sold 25000.0 shares on Mar 31 ’25.
